Two Cornell undergraduates are among a very select group of students, nationwide, chosen to receive 2003 Rhodes Scholarships for two or three years of study at Oxford University in England.
New York, NY (December 9, 2002) -- Gleevec, the new anti-leukemia drug from Novartis Pharmaceuticals, achieves a marked improvement in survival even for patients in the accelerated phase of chronic myeloid leukemia (CML), according to a study to be presented on Monday afternoon, Dec. 9, at the meeting of the American Society of Hematology (ASH) in Philadelphia.Comments Dr. Richard T. Silver, a professor at Weill Cornell Medical College and Attending Physician at NewYork-Presbyterian Hospital Weill Cornell Medical Center, who will present the findings: "Until now, the story of this disease has been like the story of Sisyphus who was condemned by the gods to roll a great stone up a mountain for all eternity. Gleevec has brought us a lot closer to the mountaintop than we've ever been."
A New York physician who has played a leading role in testing the Novartis drug Gleevec against leukemia is also finding it effective against a second disease involving blood-cell overproduction.
Barbara T. Abrams, associate director of financial aid at Cornell University, has been elected to a three-year term on the board of directors of the National Indian Education Association (NIEA).
Rebecca Sparrow, director of career services for the Cornell University School of Industrial and Labor Relations, has been named director of Cornell Career Services, Edna Dugan, assistant vice president for student and academic services, announced/
New York and Toronto (December 4, 2002) -- Study findings from the Department of Public Health at NewYork-Presbyterian Hospital Weill Cornell Medical Center and the Inner City Health Research Unit at St. Michael's Hospital/University of Toronto demonstrate that screening and treating new immigrants from developing nations for the latent stage of tuberculosis infection would result in substantial public health and economic benefits. Results are published in the December 5 issue of "The New England Journal of Medicine."Lead author Dr. Kamran Khan conducted his research in the United States while a resident/fellow in preventive medicine in the Department of Public Health at Weill Cornell. He is currently a specialist in infectious diseases and public health, and a clinician-scientist at St. Michael's in Toronto.
Cornell Law School Professor Larry Palmer, a nationally renowned expert on health policy and law, will join the Institute for Bioethics, Health Policy and Law in Louisville, Ky., in January 2003.
From dangerously rundown houses in rural upstate New York to urban shantytowns in Latin America, substandard housing is a growing international problem linked to globalization and poverty.
New York, NY (December 2, 2002) -- A widely available dietary supplement, coenzyme Q10, has shown promising results in a clinical trial involving 80 patients with early Parkinson's disease, according to a recent article in the "Archives of Neurology." In the trial--a multicenter, randomized, placebo-controlled, double-blind, and dosage-ranging trial--coenzyme Q10 was shown to be safe, well-tolerated, and significantly effective in slowing the progression of the neurological disorder. And it was clearly dose-dependent - that is, the larger the dose, the greater its effect."Our results are so encouraging that we have to emphasize that they still have to be confirmed by a Phase III clinical trial with a larger group of patients," said Dr. Flint Beal, Chairman of the Department of Neurology and Neuroscience at Weill Cornell Medical College and one of the authors of the article. He and his colleagues caution that the findings may not extend to patients with later stages of Parkinson's or to patients who are at risk but have not been diagnosed with the disorder. Furthermore, if too many people now buy coenzyme Q10 on their own, there may not be enough subjects for a rigorous Phase III trial.